Form 4: Sutro Biopharma CEO Jane Chung Reports RSU Settlement

Sutro Biopharma's CEO and Director, Jane Chung, reported the settlement of Restricted Stock Units and related tax withholding, following a 1-for-10 reverse stock split.

Summary

• Jane Chung, CEO and Director of Sutro Biopharma, Inc. (STRO), reported transactions on December 12, 2025, reflecting the settlement of equity awards.
• Acquired 2,500 shares of Common Stock through the settlement of Restricted Stock Units (RSUs) at a price of $0.
• Disposed of 894 shares of Common Stock at $8.015 per share to satisfy income tax withholding obligations in connection with the RSU settlement.
• Following these transactions, Jane Chung directly beneficially owns 13,891 shares of Common Stock.
• The reported RSU transaction represents the deferred vesting and settlement of a tranche of an award, with the RSUs vesting 1/4th annually, starting December 1, 2024.
• All reported amounts, including dollar values, have been adjusted to reflect a 1-for-10 reverse stock split that became effective on December 3, 2025.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction involving the settlement of Restricted Stock Units and subsequent tax withholding for the CEO. While it reflects an increase in direct beneficial ownership, it is a pre-scheduled compensation event rather than a discretionary purchase. The reverse stock split is a corporate action that has already been announced and implemented.

Positives

• CEO Jane Chung increased her direct beneficial ownership of common stock by 1,606 shares (2,500 acquired 894 disposed for tax) through the settlement of RSUs, indicating continued equity interest in the company.
• The RSU settlement is a pre-scheduled event, reflecting the company's compensation structure and vesting schedule.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the scheduled vesting of RSUs.

Management Comments

• The reported transaction represents the deferred vesting and settlement of a tranche of this award pursuant to the terms of the reporting person's award agreement with the Issuer.

Industry Context

This Form 4 filing reflects a routine insider transaction related to equity compensation, common across the biotechnology industry for executive retention and alignment of interests. The reverse stock split, however, is a more significant corporate action often undertaken by companies to increase their share price and meet listing requirements or attract institutional investors, which could be a broader industry trend for smaller cap biopharma companies.

Comparison to Industry Standards

• The RSU vesting and settlement, along with the associated tax withholding, are standard practices for executive compensation in publicly traded companies, particularly in the biotechnology sector.
• The 1-for-10 reverse stock split is a corporate action often undertaken by companies to improve stock liquidity or meet exchange minimum price requirements, a common strategy among smaller-cap biopharma firms.

Corporate Governance

Related Party Transactions

• The RSU settlement is a transaction between the company and its CEO, which is a related party transaction as part of executive compensation. The disposition of shares for tax withholding is a direct consequence of this.

Stakeholder Impact

• Shareholders: The reverse stock split reduces the number of outstanding shares and increases the per-share price proportionally, but does not change the total value of their holdings. The CEO's increased direct ownership aligns her interests with shareholders.
• Management: The CEO's equity compensation is being realized as per schedule.

Next Steps

• Continued vesting of remaining RSU tranches as per the award agreement.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled RSU settlement and associated tax withholding by the CEO, Jane Chung. While it results in a net increase in her direct beneficial ownership, it is not a discretionary purchase indicating new conviction. The 1-for-10 reverse stock split, which is reflected in the reported figures, was a previously announced corporate action. These events are generally expected and do not provide new fundamental information to warrant a change in investment thesis. Investors should hold and monitor future operational and financial performance.

Keywords

Sutro Biopharma, STRO, Jane Chung, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Split, CEO, Director, Equity Compensation